Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy
Nahirya-Ntege, P.; Musiime, V.; Naidoo, B.; Bakeera-Kitaka, S.; Nathoo, K.; Munderi, P.; Mugyenyi, P.; Kekitiinwa, A.; Bwakura-Dangarembizi, M.F.; Crawley, J.; Munderi, P.; Nahirya-Ntege, P.; Aber, M.; Kaggwa, F.N.; Kaleebu, P.; Katuramu, R.; Kyalimpa, J.H.; Lutaakome, J.; Matama, L.; Musinguzi, M.; Nabulime, G.; Ruberantwari, A.; Sebukyu, R.; Ssekamatte, I.M.; Tushabe, G.; Wangi, D.; Mugyenyi, P.; Musiime, V.; Afayo, V.D.; Bagurukira, E.; Bwomezi, J.; Byaruhanga, J.; Erimu, P.; Karungi, C.; Kiz
Pediatric Infectious Disease Journal 30(6): 535-537
2011
ISSN/ISBN: 1532-0987 PMID: 21164384 DOI: 10.1097/inf.0b013e3182076864Document Number: 219684
Hypersensitivity reactions are reported in approximately 5% of adults receiving abacavir, but there are few published data in children. Among 1150 African children receiving antiretroviral therapy in a randomized trial, suspected hypersensitivity reactions to abacavir were rare (0.3%; 95% CI, 0.01-0.9). Patients were managed successfully through the provision of clear guidelines and education of clinical staff, children, and their caregivers.